
Insulet (PODD) Stock Forecast & Price Target
Insulet (PODD) Analyst Ratings
Bulls say
Insulet is attractive because its Omnipod franchise combines a differentiated tubeless, pharmacy-channel patch pump with a large, underpenetrated global diabetes market, supporting a multi-year growth runway and roughly 31% share in a 14MM-patient opportunity. Recent execution reinforces that view: 3Q revenue of $842M rose 19.6% cc, adj. EPS reached $1.99, gross margin expanded to 74.2%, and operating margin reached 22.0%, while FY26 guidance was raised at the low end on improved OUS momentum. Even with softer U.S. growth and future competition risks, the board’s $1B buyback authorization and management’s continued path toward double-digit growth, margin expansion, and stronger EPS drop-through underscore durable fundamental value.
Bears say
Insulet is facing a deteriorating fundamental backdrop as management guided 2027 U.S. growth to the low end of the prior 9%-14% range and total company growth to modestly below the mid-teens, signaling decelerating demand rather than a reacceleration. The core issue is weakening Type 2 retention and churn, while stable pricing and utilization offer little offset and international growth is set to slow as the Dash-to-Omnipod 5 conversion matures beyond 80% and large launches are anniversaried. At the same time, intensifying tubeless competition and trialing, combined with limited contribution from new launches and an apparent credibility overhang from a suspended long-term framework, leaves downside risk to margins, estimates, and valuation.
This aggregate rating is based on analysts' research of Insulet and is not a guaranteed prediction by Public.com or investment advice.
Insulet (PODD) Analyst Forecast & Price Prediction
Start investing in Insulet (PODD)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Insulet (PODD) Forecast
Insulet (PODD) Analyst Forecast & Price Prediction
Start investing in Insulet (PODD)
Order type
Buy in
Order amount
Est. shares
0 shares